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A critical step in establishment of human pregnancy is the
invasionof theuteruswall by theextravillous cytotrophoblast
(EVCT), a process regulated by multiple autocrine and para-
crine factors. Hormones belonging to the GH/prolactin family
are expressed at the maternofetal interface. Because they are
involved in cell motility in various models, we examined the
possible regulatory role of human placental GH (hPGH) in
EVCT invasiveness. By using an in vitro invasion model, we
found that EVCT isolated from first-trimester chorionic villi
and cultured on Matrigel secreted hPGH and expressed hu-
man GH receptor (hGHR). These data were confirmed by in
situ immunohistochemistry. EVCT expressed the full-length
and truncated forms of hGHR, and the Janus kinase-2/signal
transducer and activator of transcription factor-5 signaling
pathway was activated in EVCT by hPGH treatment. Strong
hPGH and hGHR expression was observed when EVCT in-
vaded Matrigel and moved through the pores of the filter on
which they were cultured. hPGH stimulated EVCT invasive-
ness, and this effect was inhibited by a Janus kinase-2 inhib-
itor. Interestingly, hPGH was more efficient than pituitary
GH in stimulating EVCT invasiveness. These results offer the
first evidence for a placental role of hPGH and suggest an
autocrine/paracrine role of hPGH in the regulation of tropho-
blast invasion. (Endocrinology 146: 2434–2444, 2005)
THE HUMAN PLACENTA produces a GH [human pla-cental GH (hPGH)] specific to this organ. hPGH is the
product of the GHv gene and shows a high degree of identity
with pituitary GH (hGH), from which it differs by only 13
amino acids and anN-glycosylation site (for review see Refs.
1, 2). Expressed by the syncytiotrophoblast layer, bordering
the floating villi (3, 4), hPGH is released into the maternal
bloodstream. Its concentration increases as pregnancy
progresses, whereas that of pituitary GH falls to a nadir.
Human PGH is an important regulator of maternal metab-
olism. Through its nonpulsatile secretion and its modulation
of IGF-I expression, hPGH is considered as a major mediator
of the insulin resistance observed during pregnancy and has
been shown to directly augment insulin resistance in trans-
genic mice (5). Human PGH displays classical GH biological
effects through its binding to the GH receptor (GHR), a type
I cytokine receptor. GHR possesses a single transmembrane
domain and lacks intrinsic kinase activity. Binding of oneGH
molecule to predimerized GHR induces conformational
changes in the receptor complex (6), leading to its activation
and signaling through activation and phosphorylation of
Janus kinase-2 (JAK2), a receptor-associated protein (7). Two
alternatively spliced transcripts of hGHRhave been reported
in different human tissues, generating truncated isoforms of
the hGHR devoid of signaling activity (hGHRtr) (8, 9).
Although GHR is expressed in third-trimester placentas
(10, 11), the involvement of hPGH in placental development
and trophoblast differentiation has not yet been docu-
mented.
The human placenta is a villous hemochorial placenta
characterized by extensive invasion of thematernal uterus by
the trophoblast, placing the trophoblast in direct contactwith
maternal blood. This invasion is ensured by extravillous
cytotrophoblasts (EVCT). At the base of anchoring villi,
EVCT form clusters of proliferating cells (proliferating ex-
travillous cytotrophoblasts, PEVCT) known as columns and
then differentiate into nonproliferative highly invasive cells
(interstitial extravillous cytotrophoblasts, IVECT) that colo-
nize the decidualized endometrium and the proximal third
of the myometrium. Some EVCT invade the uterine spiral
arteries and modify their walls, replacing endothelial cells
and intercalating within the muscular tunica (12, 13). This
artery remodeling results in low-resistance, high-capacitance
vessels capable of ensuring the increased blood flow neces-
sary for placental development. Decidual invasion by EVCT
results from classical steps of cellular invasion, including
attachment to the basement membrane followed by detach-
ment and proteolysis of the basement membrane before its
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penetration. EVCT leaving the proliferative cell cluster ac-
quire an invasive phenotype characterized by a switch in
their adhesion molecule expression (14–16) and the produc-
tion of a set of proteases, metalloproteinases, (17–20), serine
proteases (21), and cathepsin (22), which degrade the extra-
cellular matrix. Decidual cells restrain this degradation by
secreting metalloproteinase inhibitors (TIMP) (23–25). They
also produce a set of growth factors, cytokines, and chemo-
kines that either inhibit or promote EVCT invasion (23, 26–
29). EVCT invasiveness is also modulated by hormones,
growth factors, cytokines, and protease inhibitors produced
by EVCT themselves (25, 26, 30). Receptors for some of these
factors are expressed in decidual cells or in EVCT (23, 26).
Consequently, EVCT invasiveness is regulated not only by
decidual cells-EVCTparacrine dialogue but also by autocrine
regulation loops acting on EVCT (23, 31, 32). The cellular
matrix and fibroblast of the villous mesenchyme are also
involved in this invasion process (33, 34). Any disruption of
these autocrine-paracrine regulations may potentially affect
the course of pregnancy, leading to disorders such as pre-
eclampsia and intrauterine growth retardation that are char-
acterized by trophoblast shallow invasion (13).
GH is involved in the regulation of cellmotility and spread
in various cellular models (35–38). In addition, hPGH is
expressed by extravillous trophoblasts located in the pla-
cental basal plate (39). We therefore investigated the poten-
tial effect of hPGHon human trophoblast invasiveness in our




Recombinant human pituitary GH (hGH) was from Pfizer (Mon-
trouge, France). The JAK2 inhibitor AG490 was from Euromedex
(Souffelweyersheim, France). Monoclonal antibodies (mAb) directed
against the following antigens were used: cytokeratin 7 (CK7; Dako,
Trappes, France), human PGH/hGH (mAb 5B4; Biocode, Sclessin, Bel-
gium), humanGHR (mAb 263; AmericanDiagnostica, Andresy, France),
fibroblast-specific antigen (clone ASO2; Dianova, Hamburg, Germany),
human leukocyte antigen (HLA) class I (HLA-A, -B, -C, -G, and -E,
W6/32; Leinco Technologies Inc., St. Louis, MO), and 5-integrin sub-
unit (CD49e; Immunotech, Marseille, France). IgG controls were from
Coulter (Fullerton, CA) for mouse IgG1 and from Immunotech for
mouse IgG2a. Fluorescein isothiocyanate-conjugated donkey antimouse
IgG (HL) was from Jackson ImmunoResearch Laboratories (West
Grove, PA). Culture medium, fetal calf serum (FCS) (Myoclone), pen-
icillin, streptomycin, and DNA size markers (-X-174 RF/HaeIII) were
from Life Technologies, Inc. Invitrogen (Cergy Pontoise, France). Tryp-
sin was from Difco Laboratories (Detroit, MI), DNase type IV was from
Sigma (Saint-Quentin Fallavier, France), Percoll was from Amersham
Biosciences (Orsay, France), and Matrigel was from BD Biosciences (Le
Pont de Claix, France).
Tissues
For cell cultures, samples of first-trimester placentas (7–10 wk) were
obtained from women undergoing voluntary elective termination of
pregnancy at Broussais Hospital (Paris, France). Samples for immuno-
histochemistry were collected in the Department of Obstetrics and Gy-
necology at La Citadelle Hospital (Lie`ge, Belgium). In both hospitals,
informed consent was obtained from the patients.
EVCT isolation and purification
EVCT were prepared as previously described (40) with minor mod-
ifications. Briefly, placental tissue was washed in Ca2- and Mg2-free
Hanks’ balanced salt solution supplemented with 100 IU/ml penicillin
and 100 g/ml streptomycin. Chorionic villi were dissected, carefully
removing blood vessels and clots, and then rinsed and submitted tomild
enzymatic digestion in Hanks’ solution containing 0.125% trypsin, 4.2
mmMgSO4, 25 mmHEPES, and 50 Kunitz/ml DNase type IV for 35 min
at 37 C without agitation. After sedimentation, supernatants were col-
lected and the remaining tissue was rinsed four times with Hanks’
solution. The sedimentation supernatants were pooled and filtered
(100-m pore size). To avoid cell aggregation, supernatants were sup-
plemented with EDTA (1 mm final concentration) and incubated for 5
min; then trypsin activity was neutralized with 10% FCS. Cells were
centrifuged (300 g for 10 min) and washed once in Hanks’. Cells were
then pelleted, resuspended in Hanks’, carefully layered on a discontin-
uous Percoll gradient, and centrifuged for 35 min at 1000 g. The layers
corresponding to 40–60% Percoll were collected (60% layer not in-
cluded) and washed twice with Hanks’/10% FCS. The EVCT prepara-
tion was further purified by plating in HAM F12/DMEM (F12/
DMEM)/10% FCS in plastic dishes at 20,000 cells/cm2. After incubation
overnight in humidified air/5% CO2 at 37 C, villous trophoblasts, mac-
rophages, and fibroblasts adhered to the plastic dishes. Floating cells
consisted mainly of EVCT and a few remaining fibroblasts. EVCT were
depleted of fibroblasts by magnetic separation using MACS antifibro-
blast MicroBeads according to the manufacturer’s instructions (Miltenyi
Biotec, Bergisch Gladbach, Germany). Briefly, after centrifugation, the
cell pellet was resuspended in 80 l PBS/0.5% FCS and incubated with
20 l antifibroblast MicroBeads for 30 min at 20 C. The cells were then
washed and separated on an MS MACS magnetic column. Three mil-
liliters of PBS/0.5% FCS were applied to the column to wash out EVCT
(column eluate), fibroblasts remaining bound to the column. To recover
fibroblasts, the column was removed from the magnet and flushed with
PBS/0.5% FCS. The fibroblastic nature of the flushed cells was checked
by immunocytochemistry (ASO2-positive, CK7-negative). EVCT were
centrifuged, and then the pellet was resuspended in F12/DMEM/10%
FCS and plated in culture chambers or submitted to RNA extraction (see
below).
Insert culture of extravillous cytotrophoblasts
The culture chambers consisted of high-throughput samples (HTS)
FluoroBlok inserts (24-multiwell insert system; BD Biosciences). The
bottom of the insert is composed of a light-tight polyethylene tereph-
talate pored filter (pore size, 8 m) that blocks the transmission of
wavelengths from 490–700 nm. Invasive cells can move from the upper
to the lower face of the filter through pores and can be visualized by
immunofluorescence. The polyethylene terephtalate filter blocks fluo-
rescence emitted by cells present on the reverse face of the filter. EVCT
(2.5  105 cells) were plated on the filters (1 cm2) coated with Matrigel
(10 l, 5 mg/ml). Inserts were placed in wells (4 cm2), and the inserts
and wells were filled with culture medium (DMEM/F12, 2 mm glu-
tamine, 100 IU/ml penicillin, and 100 g /ml streptomycin) supple-
mented with 10% FCS (200 l in the insert and 600 l in the well) and
placed at 37 C in a humidified atmosphere of 5% CO2 in air. In some
experiments, plating was interrupted after 30 min or 3 h, and cells were
fixed for immunocytochemistry as described below. Otherwise, the me-
dium was replaced after 2 h with the same medium supplemented with
1% FCS and various treatments (see below). For immunocytochemistry,
insertswere filledwith culturemedium supplementedwith 2%FCS, and
wells were filled with culture medium supplemented with 20% FCS,
creating an invasion-promoting serum gradient. After 72 h, cells were
washed three times with PBS, fixed for 20 min in 4% paraformaldehyde,
and washed again three times in PBS. Inserts containing fixed cells were
stored in PBS at 4 C for no longer than 2 d until immunodetection assays.
Invasion assays
For invasion assays, inserts and wells were filled with culture me-
dium supplemented only with 1% FCS (to reduce the effect of growth
factors present in FCS on EVCT invasiveness). Various concentrations of
hGH, hPGH, or human prolactin (hPRL) were added to the medium on
both sides of the filter. The same concentrations were again added to the
medium after 40 h of culture, without renewing the medium. In some
experiments, a JAK2 inhibitor (AG490) dissolved in dimethylsulfoxide
(DMSO) was added to the medium in the same conditions. In these
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experiments the same concentration of DMSO (1/1000) was added to
control wells. This concentration of DMSO did not affect cell viability,
as tested by trypan blue exclusion, and no nuclei condensation or frag-
mentation was observed by 4,6-diamidino-2-phenylindole (DAPI)
staining. After 72 h, culture supernatants were collected from control
wells to evaluate hPGH production, and the number of invasive cells
present on the underside of the filter (entire surface) was scored visually
after CK7 immunolabeling. Briefly, cells were fixed in 4% paraformal-
dehyde as described in the previous section and permeabilized for 8min
in methanol at 20 C. After 1 h of incubation at room temperature in
PBS supplemented with 10% donkey serum and 10% horse serum to
reduce nonspecific binding, the cells were incubated with CK7 antibody
(1 g/ml) diluted in PBS/10% donkey serum/10% horse serum for 2 h
at room temperature. The cells were washed in PBS/0.1% Tween and
incubated with fluorescein isothiocyanate-conjugated antimouse IgG
(4.6 g/ml) for 1 h in the dark and were then washed in PBS/0.1%
Tween. The filters were removed from the inserts with a scalpel and
mounted on a microscope slide in a drop of mounting medium con-
taining 1.5 g/ml DAPI (Vectashield, Vector Laboratories, Burlingame,
CA), with the underside of the filters facing upward. Invasion was
scored by counting the cells on the underside of the filters with an
Olympus BX60 epifluorescence microscope. Experiments were repeated
at least four times (see figure legends) with EVCT from different pla-
centas, and inserts were prepared in duplicate for each experimental
condition. To minimize interexperiment variability, the number of cells
scored on the underside of the filters in treated chambers was expressed
as a percentage (invasion index) of the number of cells scored on the
underside of the filter in the control chamber.
Immunohistology
Paraffin-embedded sections were kindly supplied by Prof. Foidart
(Pathology Department of La Citadelle Hospital, Lie`ge, Belgium). Sam-
pleswere fixed by incubation in 4% formalin for 4 h at room temperature
and then embedded in paraffin, dewaxed in xylene, and rehydrated in
ethanol/water. Antigen retrieval was done by immersing the slides for
40 min in Dako retrieval solution (pH 6) preheated at 90 C in a water
bath. Immunostaining was performed with a universal streptavidin
peroxidase immunostaining kit (Dako LSAB System horseradish per-
oxidase). Endogenous peroxidase-like enzyme activity was blocked by
incubation for 5 min in a blocking reagent containing 3%H2O2. After 1 h
of saturation in PBS/10% pig serum/10% horse serum/50 g/ml hu-
man IgG (complemented PBS), sections were incubated with CK7 an-
tibody (1 g/ml), or mAb 263 (25 g/ml), or mAb 5B4 (17 g/ml) at 4
C overnight in complemented PBS. Sectionswerewashed in PBS, treated
again with H2O2 solution for 5min, and saturated in complemented PBS
for 1 h. Then they were incubated with a biotinylated secondary anti-
body for 1 h. The sectionswerewashed in PBS, and stainingwas detected
by incubation for 2minwith the 3,3-diaminobenzidine chromogen. The
slides were lightly counterstained with hematoxylin. Controls were
performed by incubating sections with nonspecific mouse IgG (same
isotype) at the same concentration.
Immunocytology
HLA class I and ASO2 immunodetection was performed on para-
formaldehyde-fixed cells. For GHR and hGH immunodetection, cells
were permeabilized with methanol as described for CK7 detection. For
5-integrin subunit immunodetection, cells were permeabilized for 4
min in 0.3% Triton X-100/PBS. After 1 h of saturation in PBS/10%
donkey serum/10% horse serum/50 g/ml human IgG, primary anti-
bodies in the same supplemented PBS buffer were added at appropriate
concentrations (ASO2, 4 g/ml; w6/32, 2 g/ml; mAb 263, 9 g/ml;
mAb 5B4, 6 g/ml; and CD49e, 1 g/ml) overnight at 4 C. Cells were
then incubated with a secondary antimouse antibody conjugated with
fluorescein (4.6 g/ml), as described for CK7, and were mounted in
Vectashield. Control experiments for each antiserum included replace-
ment of the primary antiserumwith the appropriate nonimmunemouse
IgG (same isotype) at the same concentration.
hPGH immunoradiometric assays (IRMA)
EVCT collected at the end of the purification processwere centrifuged
and sonicated in 250 l of 10 mm Tris/HCl, 20 mm sodium molybdate,
0.6 mm KCl, 1 mm EDTA, and antiprotease inhibitor cocktail (set I;
Calbiochem, La Jolla, CA). Culturemedium (1% FCS)was collected after
72 h of culture, concentrated onMicrocon YM-30 (AmiconMillipore Co.,
Bedford, MA), and evaporated under a gentle stream of nitrogen. The
residue was reconstituted with 200 l IRMA buffer. Known hPGH
concentrations extracted in the same way gave a mean recovery of 84
5%. hPGH was measured in duplicate in a specific solid-phase 125I-
labeled IRMA (Biocode, Lie`ge, Belgium) using two specificmAbs. Cross-
reactivity is 100% for hPGH and less than 0.001% for hGH and human
placental lactogen. The detection limit is 200 pg/ml. The intra- and
interassay coefficients of variation are 4 and 6%, respectively (41, 42).
Real-time quantitative RT-PCR
Total RNA from EVCT collected before plating (time zero) and after
72 h of culture were prepared by means of the single-step guanidinium-
phenol-chloroform method described by Chomczynski and Sacchi (43).
The quality of RNA sampleswas determined by electrophoresis through
agarose gel and visualization of the 18S and 28S bands under UV light
after staining with ethidium bromide. cDNA synthesis and real-time
quantitative PCR were performed as previously described (44). PCR
were run in an ABI PRISM 7700 Sequence Detection System with the
SYBR Green (Bcl-2 and Ki-67) or TaqMan (GHv and GHR) PCR Core
Reagents kits (PerkinElmer Applied Biosystems, Foster City, CA). GHv,
hGHR, Bcl-2, and Ki-67 cDNAwere amplifiedwith specific forward and
reverse primers (Table 1). Transcripts of the constitutive housekeeping
gene 36B4, coding for acidic ribosomal phosphoprotein (PO) (44) were
measured in each sample to control for sample-to-sample differences in
the RNA concentration. Levels of GHv, hGHR, Ki67, and Bcl-2 mRNA
were expressed as a ratio of PO mRNA values.
TABLE 1. Oligonucleotide sequence of primers used in the real-time PCR
Genes Primer Sequence (533) PCR product size (bp)
GHv Forward primer AGA ACC CCC AGA CCT CCC T 96
Reverse primer TGC GGA GCA GCT CTA GGT TAG
Probe TTT CTG CTG CGT TTT CAC CCT GTT G
hGHR Forward primer GCA ATG GTG GTA CAG TGG ATG A 145
Reverse primer CGT GGT GCT TCC CAT CTC AC
Probe CAA CCA GAT CCA CCC ATT GCC CTC A
PO Forward primer GGC GAC CTG GAA GTC CAA CT 149
Reverse primer CCA TCA GCA CCA CAG CCT TC
Probe ATC TGC TGC ATC TGC TTG GAG CCC A
Ki-67 Forward primer ATT GAA CCT GCG GAA GAG CTG A 105
Reverse primer GGA GCG CAG GGA TAT TCC CTT A
Bcl-2 Forward primer CCC CTG GTG GAC AAC ATC GC 101
Reverse primer AGT TCC ACA AAG GCA TCC CAG C
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RT-coupled hemi-nested PCR
Total GHR transcripts from EVCT were reversed-transcribed using
the SuperScript II protocol (Invitrogen) for subsequent amplification.
The transcripts corresponding to the full-length hGHRand the truncated
form (GHRtr) isoforms were amplified with primers that flank the al-
ternative splice site located in exon 9. Two specific forward primers
located in exon 9, designated h9 (5-ATTTTCTAAACAGCAAAGGA-3)
and h9tr (5-ATTTTCTAAACAGCAAAGTT-3), respectively (8), were
used in combination with a reverse primer (h10) located in exon 10
(5-CACTGTGGAATTCGGGTTTA-3) for the first-round PCR, and a
hemi-nested primer (h10) also located in exon 10 (5-GATTGTGT-
TCACCTCCTC-3) was used for the second round. Both amplification
steps were run in a thermal cycler with the following parameters: initial
denaturation for 5 min at 94 C, followed by 35 cycles consisting of 30 sec
at 94 C, 30 sec at 55 C, and 30 sec at 72 C and by a final extension step
at 72 C for 7 min. The amplification products (hGHR, 118 bp; hGHRtr,
92 bp) were detected by electrophoresis on agarose 1%/3% NuSieve gel
stained with ethidium bromide. Transcripts from human kidney were
amplified as the positive control (8), and water served as the negative
control.
Transient transfection of primary invasive EVCT and
luciferase assay
Human EVCT isolated and purified as described above (see EVCT
isolation and purification) were plated (5 105 cells per well) onMatrigel-
coated Falcon six-well cultures dishes. Transfectionwas performed after
18 h of culture by using the TransIT-LT1 transfection reagent (Mirus,
Madison, WI) as recommended by the manufacturer. Briefly, the cells
were cotransfected in complete medium containing 1% FCS for 6 h with
3 g of the reporter gene and 2 g of pCH110 (-galactosidase expres-
sion vector, Pharmacia Biotech, Inc., Piscataway, NJ). The reporter gene
carries the luciferase coding sequence under the control of a six-repeat
sequence of the lactogenic hormone response element (LHRE), followed
by the minimal thymidine kinase promoter (45, 46). The sequence of a
single LHRE DNA element is 5-CTGCAGTGTGGACTTCTTGGAAT-
TAAGGGACTTTTGCTGCAG-3, with the Stat5 consensus binding se-
quence underlined. hPGH (100 or 500 ng/ml) was then added for an
additional 18 h of culture period. Cells were lysed in 200 l lysing buffer
[25 mm Tris/H3PO4 (pH 7.8), 10 mmMgCl2, 1 mm EDTA, 15% glycerol,
1% Triton X-100], and luciferase and -galactosidase activities were
measured as follows. For luciferase, 400l lysing buffer (without Triton)
containing 1 mm dithiothreitol was added to 100 l cell lysate, and
luminescence was measured after addition of 100 l of the same buffer
containing 200 mm ATP and 100 g/ml sodium luciferin (Sigma) using
a luminometer (Lumat LB 9501, Berthold Evry, France). To measure
-galactosidase activity, 250 l of 60 mm Na2HPO4 (2 H2O), 40 mm
NaH2PO4, 10mmKCl, 1mmMgSO4 (7 H2O) (pH 7) containing 3.5 l/ml
-mercaptoethanol was added to 80 l cell lysate and incubated at 37 C
for 2 hwith 100l ortho-nitrophenyl galactopyranoside (4mg/ml) in 100
mm phosphate buffer (pH 7) before reading the OD at 420 nm. Arbitrary
luciferase units were normalized for -galactosidase activity, and results
were expressed relative to untreated controls.
Statistical analysis
Results are shown as means  sem of at least four independent
experiments with individual placentas, each run in duplicate. Statistical
analysis was performed using the Stat View F-4.5 software package
(Abacus Concepts, Inc., Berkeley, CA). The effects of treatments on the
EVCT invasion index were tested using the nonparametric Kruskall-
Wallis (ANOVA) test for multiple comparisons and the Mann-Whitney
U test for pairwise comparisons. P values  0.05 were considered
significant.
Results
In vitro model of EVCT invasion (Fig. 1)
Figure 1A (left) shows an invasion chamber with EVCT
plated on a Matrigel-coated filter. After 30 min of plating,
cells were phenotyped as EVCT by immunohistochemical
staining with CK7 antibody, W6/32 antibody against HLA
class I molecules [including HLA-G, HLA-C and HLA-E
expressed by EVCT (47, 48)], and ASO2 antibodies. Purity of
the cell population, assessed by positive immunostaining
with CK7 (Fig. 1B, e) and W6/32 (Fig. 1B, a) antibodies and
negative immunostaining with AS02 antibody (not shown),
was more than 95% (95–100% from one experiment to an-
other). Fibroblast contamination was less than 1% (ASO2-
positive cells; not shown). After 3 h of plating, including a
medium change after 2 h, all these cells expressed5-integrin
subunit (Fig. 1B, i). After 34 h of culture, EVCT started to
move to the lower face of the filter (Fig. 1A, right). Prelim-
inary migration assays, including in 1% FCS, showed that
maximal EVCT invasion occurred at 72 h (not shown), and
this time point was used for subsequent experiments.
Autocrine regulation of EVCT invasion (Fig. 2)
EVCT were plated on Matrigel-coated filters (2.5  105
cells), and the inserts were placed in three types of wells:
normal (control), cell-free wells coated with Matrigel (Ma-
trigel control), and wells coated with Matrigel, on which
EVCT from the samepreparation had been plated at the same
time at two cell densities (1.5 or 4.5  105; Fig. 2, top). After
72 h of culture, the EVCT migration index was similar in
control wells and in Matrigel control wells. The migration
index of EVCT grown in inserts placed in EVCT-plated wells
was significantly higher than control values. The number of
EVCT on the lower face of the filters increased with the
number of EVCT plated on the bottom of the wells (Fig. 2,
bottom; P  0.01).
Expression of hPGH by EVCT (Figs. 3 and 4)
Expression of GHv mRNA in EVCT (Fig. 3A). Total RNA pre-
pared from EVCT collected before plating (0 h) and after 72 h
of culture was reverse transcribed and analyzed by real-time
quantitative RT-PCR. GHv transcript levels were similar at
the two time points.
Immunodetection of hPGH in cultured EVCT. hPGH immuno-
staining was detected in isolated EVCT at each time of cul-
ture considered. Figure 3B (a), shows hPGH signal in inva-
sive EVCT at 72 h of culture. Immunostaining was also
detected in EVCT observed after 30 min and 15, 48, and 60 h
of culture (data not shown).
Immunodetection of hPGH in situ (Fig. 4)
Paraffin sections of first-trimester anchoring villi were
subjected to immunohistochemical analysis with antibody
against hPGH. hPGH immunoreactivity was detected in the
villous trophoblasts at the syncytiotrophoblast level (Fig. 4B,
left, ) and in invasive IVECT (Fig. 4B left, white triangles). A
relatively higher level of GH expression was present in the
syncytiotrophoblast, compared with invasive EVCT. Very
faint, even absent signal, was observed in the PEVCT of the
column (Fig. 4B, left, black arrow). CK7 immunostaining was
used as a specific trophoblast marker (Fig. 4A, left).
EVCT hPGH content and hPGH production (IRMA). hPGHwas
detected and quantified in EVCT before plating. The mean
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cellular hPGH content was 47 22 pg/106 cells (mean sem;
n 6). hPGHwas detected in EVCT culturemedium after 72 h
of culturewithoutmediumchanges (meanconcentration, 235
90 pg/ml per 2.5  105 cells; mean  sem; n  6).
hGHR expression by EVCT (Figs. 4 and 5)
HGHR mRNA (Fig. 5A). Real-time PCR was used to detect
hGHR transcripts in the same RNA samples as those used for
GHvmRNAdetection. EVCT expressed hGHR transcripts at
both 0 and 72 h of culture. The expression level tended to
decrease between 0 and 72 h of culture, but the differencewas
not significant (GHR mRNA/PO arbitrary units, 6  2.5 vs.
3.7  0.9, respectively; n  7).
Expression of the truncated isoform of human GHR in
EVCT (Fig. 5B)
RNA isolated from EVCT collected at time zero were re-
verse transcribed and analyzed by semi-nested PCR. As
shown in Fig. 5B, full-length (l; 118 bp) and truncated (tr; 92
bp) hGHR isoforms were detected in EVCT.
Immunodetection of hGHR in cultured EVCT (Fig. 5C)
hGHR-immunostained cells were observed on the upper
side of the filter at each culture time studied (30 min and 15,
48, 60, and 72 h; 30 min and 15 and 60 h not shown). Cells
were organized as clusters and displayed various labeling
intensities. Figure 5C (a) shows such a cluster observed after
48 h of culture; cells leaving the cluster to invade Matrigel
were more intensely stained (arrow). At 72 h, most immu-
nostained cells were observed on the upper side of the filter;
invasive EVCT with pseudopods engaged in pores were
strongly stained (Fig. 5C, c). EVCT, which had completely
invaded Matrigel and crossed the filter, showed little or no
staining (Fig. 5C, e).
Immunodetection of hGHR in situ (Fig. 4)
Paraffin sections of first-trimester anchoring villi were
subjected to immunohistochemical analysiswith anti-hGHR.
GHR immunoreactivity was detected in the villous tropho-
blasts (cytotrophoblast and syncytiotrophoblast) bordering
the villi (Fig. 4C, left, ), in PEVCT of the column (Fig. 4C, left,
FIG. 1. In vitromodel of trophoblast invasion. A, In vitro
model used to study trophoblast invasion (left). The cul-
ture chamber used for the invasion assay consisted of a
plastic well containing an insert with a Matrigel-coated
filter. EVCT were plated on the filter and cultured for
72 h (CM, culture medium). Invasive EVCT crossing the
filter through pores (arrow) were visualized on the un-
derside of the filter by CK7 immunostaining (right) and
scored. B, EVCT immunophenotyping. Immunodetec-
tion ofHLA class I (a) andCK7 (e)was performed on cells
30 min after plating. Immunodetection of 5-integrin
subunit (i) was performed 3 h after plating. No staining
was observed when EVCT were incubated with the IgG
isotype control (c, g, and k). Nuclei were stained with
DAPI (b, d, f, h, j, and l). Scale bar, 30 m.
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black arrow) and in invasive IEVCT (Fig. 4C, left, white
triangles).
Activation of JAK2-Stat5 cascade by hPGH in EVCT
(Fig. 5D)
To investigate the ability of hPGH to activate the JAK2-
Stat5 signaling pathway in EVCT, we used EVCT transiently
cotransfected with the LHRE promoter luciferase construct
along with the -galactosidase construct to correct for vari-
ations in transfection efficiency. As shown in Fig. 5D, treat-
ment of these cells with 100 ng/ml hPGH induced a 4-fold
increase in luciferase/-galactosidase activities (P  0.05;
n  3). Higher concentration (500 ng/ml) had no significant
effect.
Stimulation of EVCT invasion by hPGH and hGH (Fig. 6)
The effects of hPGH and hGH on cell invasiveness were
tested by adding each hormone in culture media, at concen-
trations ranging from 0.2–100 ng/ml. As shown on Fig. 6,
both hPGH (Fig. 6A; n  7) and hGH (Fig. 6B; n  5) dose-
dependently enhanced the number of cells on the lower face
of the filter (P  0.01), with biological responses exhibiting
typical bell-shaped curves. Maximal activity was achieved at
20 ng/ml for both hormones. A comparative study of the
effect of both hormones at this concentration (20 ng/ml) on
EVCT invasion index showed that hPGH was significantly
more efficient than hGH (invasion indexes: hPGH, 440 
114%, n 7; hGH, 218 25%, n 10; P 0.05). hPRL tested
at 20 ng/ml (Fig. 5C) and 100 ng/ml (data not shown) had
no effect on EVCT invasion. The effect of both hPGH and
hGH on EVCT invasion was inhibited by the JAK2-specific
inhibitor AG490. Simultaneous addition of 10mAG490 and
20 ng/ml hPGH to the EVCT culture medium completely
inhibited the effect of hPGH on EVCT invasion (P 0.05; n
3; Fig. 6D). AG490 alone and DMSO alone had no effect on
EVCTmigration. In the same conditions,AG490 inhibited the
effect of hGH (data not shown). As we have previously
reported, EVCT cultured on Matrigel are invasive but not
proliferative (40). Because GH is involved in regulating prolif-
eration and apoptosis,we comparedKi-67 andBcl-2 expression
between control and hPGH-treated EVCT by quantitative RT-
PCR.EVCTexpressedvery low levels ofKi-67. hPGHtreatment
had no effect on Ki-67 expression (Ki67/PO: control 2.1  0.3
vs. hPGH 2.9  1; n  3). EVCT expressed Bcl-2, and hPGH
treatment did not affect Bcl-2 expression level (Bcl-2/PO: con-
trol 3.13  0.7 vs. hPGH 4.3  1.6; n  3).
FIG. 2. Autocrine regulation of EVCT invasion.Top, EVCT (2.5 105
cells) were plated in inserts on Matrigel-coated filters. The inserts
were then placed in normal wells (control O), inMatrigel-coated wells
without cells (Control OM), or in Matrigel-coated wells with EVCT
plated on the bottom (1.5 or 4.5  105 cells prepared from the same
placenta; Autocrine device). Bottom, After 72 h of culture, EVCT that
had moved to the underside of the filters were scored after CK7
immunostaining. Results are expressed as the percentage of cells
scored on the underside of the filter insert in control wells (invasion
index). Values represent the mean of duplicate determinations for
four independent cultures established from different placentas. *,P
0.05; **, P  0.001.
FIG. 3. hPGH expression by EVCT. A, GHv mRNA levels were mea-
sured by real-time quantitative RT-PCR in EVCT collected before
plating (0 h) and after 72 h of culture. GHv mRNA levels were nor-
malized to PO mRNA levels. Values are the mean of PCR values for
seven independent experimentswith cells fromdifferent placentas. B,
Immunodetection of hPGH in EVCT, 72 h after plating on Matrigel-
coated filters; a, hPGH expression by an invasive EVCT that has
nearly completed crossing the membrane through a pore (arrowhead;
lower side of the filter visualized). No staining was observed when
cells were incubated with the IgG isotype control (c). Nuclei were
stained with DAPI (b and d). Scale bar, 30 m.
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Discussion
We investigated the possible involvement of hPGH in the
regulation of trophoblast invasion at the fetomaternal inter-
face in early stages of pregnancy. By using an in vitromodel
we found that hPGH and hGHR were expressed by invasive
EVCT and that hPGH stimulates EVCT invasiveness.
Various cell culturemodels have been used to study EVCT
invasion. Immortalized trophoblast cell lines are extensively
used, but these cells do not express all themarkers of primary
EVCT (for review seeRef. 49). EVCTused for primary culture
are obtained either by trophoblast outgrowth from placental
explants, a method that preserves interactions between tro-
phoblasts and adjacent stroma (50), or after enzymatic di-
gestion of villi fragments (51). We used EVCT isolated from
first-trimester placenta by a gentle enzymatic digestion pro-
cedure (40, 52) modified to further deplete fibroblasts. The
EVCT thus obtained were phenotyped by CK7 and HLA
class I immunostaining (47–49, 53). Isolated EVCT grown in
Matrigel-coated Transwell chambers behave as previously
described in anchoring villi explants models; they aggregate
in clusters and, at the periphery of these clusters, the cells
grew pseudopods and invade Matrigel. As we previously
reported, in these culture conditions, EVCT rapidly acquire
an invasive phenotype as they express specific markers such
as integrin 51 (observed after 3 h of plating in these ex-
periments) and the protooncogene c-erbB2 (40).
We also showed that, in our culture system, isolated pu-
rified EVCT regulated their own invasiveness. This up-reg-
ulation was not a nonspecific effect explained by a higher
concentration of growth factors in the culture medium be-
cause ofMatrigel spread on the bottom of the well (54). It did
not result either from a paracrine interaction with fibroblasts
of the mesenchymal core, as described by Aplin et al. (33),
because our EVCT preparation was depleted of fibroblasts.
Because the twopopulations of EVCTwere not in contact, the
EVCT plated on the bottom of the wells therefore increased
the invasiveness of EVCT plated on filters by the release of
soluble factors in the culture medium. There is now evidence
that soluble factors produced by EVCT such as IGF-II (55),
endothelin-1 (56), urokinase-type plasminogen activator (21)
or heparin-binding EGF-like growth factor (28) regulate
EVCT migration/invasiveness in an autocrine manner.
Among the hormones produced by trophoblasts, hPGH
could be involved in an autocrine/paracrine regulation of
trophoblast invasiveness, because hGH has been implicated
in invasion in various cellular models.
We found that isolated EVCT expressed GHv mRNA.
They also produced hPGH (detected in cell extracts) and
released it in the culture medium. In our culture model,
EVCT expressed hPGH as they acquired an invasive phe-
notype. PGH staining was observed from the first hours of
the culture up to 72 h.We previously found that, 90min after
plating on Matrigel, 42% of the trophoblasts already express
51-integrin (reflecting an invasive phenotype; (40). In this
study, we found that after 3 h of culture, all EVCT expressed
5-integrin subunit. The strongest hPGH staining was ob-
served in invasive EVCTs thatweremoving through the filter
pores. These data fit with a recent report that autocrine hGH
production by mammary carcinoma cells transfected with
the hGH gene increases the migration and invasive potential
FIG. 4. GH and GHR immunodetection in first-
trimester anchoring villi. Paraffin sections of
first-trimester anchoring villi underwent immu-
nohistochemical analysiswith antibodies against
GH, GHR, and CK7. A, Right, Scheme of an an-
choring villus at the implantation site: villous
cytotrophoblasts (yellow) and syncytiotropho-
blast (green) bordering the villi (VCT and ST; ),
PEVCT (black arrow) and IEVCT (white trian-
gles); left, CK7 antibody was used as a specific
trophoblast marker: VCT, ST, PEVCT, and
IEVCT showed strong immunoreactivity. B, Left,
GH immunoreactivitywas detected in theSTbor-
dering the villi () and in IEVCT (white triangles).
Staining was more pronounced in ST than in
IEVCT. It was very faint, even absent, in the
PEVCT of the column (black arrow). C, Left, All
types of trophoblasts, VCT and ST (), PEVCT
(black arrow), and IEVCT (white triangle)
stained with GHR antibody. B and C, Right, No
staining was observed with the IgG isotype con-
trols. Scale bar, 100 m.
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of these cells (38). Immunohistochemical analysis of first-
trimester anchoring villi showed GH staining in the villous
trophoblast bordering the villi at the syncytiotrophoblast
level and in the invasive IEVCT. This is in keeping with a
study of Jara et al. (39) in third-trimester placenta, who de-
tected hPGH by immunohistochemical staining in the syn-
cytiotrophoblast and in trophoblasts located in the placental
basal plate. GH immunostaining was undetectable in the
PEVCT of the column. This could be because of the absence
or a very low level of GH expression in these cells and/or
because of the lack of sensitivity of mAb 5B4 antibody on
paraffin sections (Lacroix, M. C., unpublished observation).
But this antibody is the only one available that does not
cross-reactwith the human chorionic somatomammotrophin
(58).
This is the first report of hGHR mRNA and protein ex-
pression by first-trimester EVCT. Other authors have de-
scribed hGHR mRNA expression in human placenta (10, 11)
and also hGHRmRNA and protein expression exclusively in
the syncytiotrophoblasts of third-trimester placenta (59, 60).
As the culture time increased, we found that only cells leav-
ing clusters and moving to the lower face of filters strongly
expressed hGHR. In contrast, EVCT already plated on the
lower face showed little or no hGHR immunostaining. hGHR
mRNA expression by EVCTwas not significantly lower after
72 h of culture than at time zero, probably because EVCT
collected at 72 h for mRNA preparation were at different
steps of the invasive process. Nevertheless, our results
strongly suggest that EVCT hGHR expression is related to
acquisition of an invasive phenotype. Immunohistochemical
analysis of first-trimester anchoring villi showed GHR stain-
ing in the villous trophoblast (cytotrophoblasts and syncy-
tiotrophoblast) bordering the villi, in the PEVCT of the col-
umn, and in the invasive IEVCT.
FIG. 5. GHR expression by EVCT. A, GHR mRNA levels were measured by real-time quantitative RT-PCR in EVCT collected before plating
(0 h) and after 72 h of culture. GHR mRNA levels were normalized to PO mRNA levels (mean  SEM; n  7). B, RT hemi-nested PCR analysis
of GHRandGHRtr isoforms inEVCT.RT-PCRproducts for full-length hGHR (l; 118 bp) and truncated hGHR (tr; 92 bp)were detected on agarose
(1%) NuSieve (3%) stained with ethidium bromide. Lanes P and K were loaded with amplified cDNA derived from EVCT and kidney (positive
control), respectively, and lane C with specimen control in which water replaced mRNA (M, size markers). Amplification of -actin was used
as procedural control and to check RNA integrity. C, GHR immunodetection was performed on EVCT at 48 and 72 h after plating on
Matrigel-coated filters. Invasive EVCT emerging from clusters to invade Matrigel show stronger immunostaining (a, arrowhead, upper side
of the filter observed at 48 h). c, Higher magnification of GHR expression in an EVCT starting to cross the membrane (upper side of the filter
observed at 72 h) through a pore (arrowhead). EVCT that had already invaded Matrigel and crossed the filter show poor or no hGHR
immunostaining (e, lower side of the filter observed at 72 h). No staining was observed when cells were incubated with the IgG isotype control
(g). Nuclei were stained with DAPI (b, d, f, and h). Scale bar, 30 m. D, Activation of the JAK2-Stat5 pathway by hPGH in EVCT. EVCT were
cotransfected with a plasmid carrying the luciferase coding sequence under the control of a six-repeat sequence of the LHRE element and the
pCH110 vector encoding -galactosidase used as internal transfection control. Cells were cultured in the presence of hPGH (100 or 500 ng/ml)
for 18 h, and luciferase activity was measured and normalized to -galactosidase activity. Results are expressed relative to controls and are
the mean  SEM of three separate cultures obtained from three different placentas. *, P  0.05.
Lacroix et al. • Human Placenta and PGH Endocrinology, May 2005, 146(5):2434–2444 2441
 at Bibliotheque de la Faculte de Med - Univ De Liege on September 17, 2008 endo.endojournals.orgDownloaded from 
Alternatively spliced transcripts at exon 9 of the hGHR
gene have been reported in human tissues, generating trun-
cated hGHR isoforms devoid of signaling capacity (hGHRtr)
(8, 9). We found that first-trimester EVCT expressed both
full-length hGHR and hGHRtr. Our results fit with those of
Dastot et al. (8), who reported that placental hGHRtr expres-
sion was higher than in other human tissues, but they ex-
tracted mRNA from fragments of whole-term placentas,
which therefore included all cell types present in the chori-
onic villi (trophoblast, fibroblast,macrophage, etc.) and in the
decidua. Dimerization of hGHRtr with a full-length hGHR
inhibits GH signaling (61). Furthermore, hGHRtr generate
more soluble GH-binding protein (8), which modulates GH
availability for the GHR (62). hPGH binds to GH-binding
proteins (63), suggesting that such regulation might take
place at the maternofetal interface.
Having shown that hGHR is expressed in EVCT, we ex-
amined the ability of hPGH to activate the JAK2-Stat5 sig-
naling pathway by binding to hGHR. We found that hPGH
treatment (100 ng/ml) of EVCT transiently transfected with
a Stat5 reporter plasmid (LHRE luciferase construct) resulted
in transcriptional induction of the reporter gene. High con-
centrations of hPGH (500 ng/ml) had no effect, probably
owing to a self-inhibition of hGHR dimerization by the for-
mation of 1:1 complexes between hormone and receptormol-
ecules (64). These data suggest that the full-length hGHR
expressed in EVCT is functional and that the binding of
hPGH on this receptor activates Stat5, a classical intracellular
protein that is phosphorylated after JAK2 activation. These
data are in keeping with the results of a previous study
showing that hPGH binding to cell lines expressing GHR
results in Stat5b activation (65).
Then we investigated the ability of hPGH to regulate
EVCT invasiveness. Addition of hPGH to the culture me-
dium of EVCT significantly increased their invasive poten-
tial. Pituitary GH also stimulated invasiveness, but to a lesser
extent. Both hormones gave bell-shaped curves in concen-
tration-response assays as classically reported for GH (64).
AG490 inhibition of both GH effects on EVCT invasion con-
firms that these effects were mediated by Janus kinase acti-
vation in this cell model. Because GH promotes cell prolif-
eration and inhibits apoptosis, we compared control and
GH-treated cells for their expression level of a proliferation
marker, Ki-67 (66), and of a cell survival marker, Bcl-2 (67,
68), after 72 h of culture. The results suggested that the
increased number of cells invading Matrigel during GH
treatment did not result from increased EVCT proliferation
or survival.
In our cellular model, hPGHwas more efficient than hGH
in increasing EVCT invasive potential. Comparative studies
of hPGH and hGH binding to somatogenic receptors have
given conflicting results. hPGH is equipotent with hGH in
binding hGHR or hGH-binding protein (2, 63) and displays
similar somatogen biological activities (2). Interestingly, al-
though both GH bind on placental microsomes (10), Igout
(70) found that hGH poorly displace radiolabeled hPGH
bound to human placental microsomes even at concentra-
tions as high as 450 nm. These data suggest that the human
placenta expresses the hGHR but also a second population
of GHRmore specific for hPGH. It has been reported that the
human placenta expresses a unique form of hGHR mRNA
deleted for exon 3 (11). However, more recent studies found
that the exon 3-deleted hGHR isoform was individual spe-
cific and not tissue specific (57, 69). Although the existence
of a placenta-specific GHR remains to be demonstrated, our
data clearly show that hPGH is more potent than hGH to
stimulate cell invasiveness in a homologous primary culture
model.
In conclusion, this study provides the first clear evidence
for a role of hPGH in the placenta. Our data show that hPGH
stimulates EVCT invasiveness and suggests an autocrine role
for hPGH at the trophoblast level. Additional studies are
needed to elucidate the role of this hormone in early pla-
centation and in pregnancy disorders associated with ab-
normal trophoblast invasion, such as intrauterine growth
retardation or preeclampsia.
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FIG. 6. EVCT invasiveness is potentiated by hPGH and hGH. A and
B, EVCT (2.5  105 cells) were grown on Matrigel-coated filters for
72 h in the presence or absence of increasing concentrations of hPGH
(A) or hGH (B). Both treatments increased EVCT invasion index,
calculated as described in Fig. 2. C, Comparative effect of PGH (20
ng/ml) and hPRL (20 ng/ml) 72-h treatment on the EVCT invasion
index. hPRL had no effect on EVCT invasion. D, EVCT were cultured
for 72 h in the absence (control) or presence of hPGH (20 ng/ml),
AG490 (10 M), or hPGH (20 ng/ml) plus AG490 (10 M). AG490
inhibited the effect of hPGH on the invasion index. Values are the
mean  SEM of duplicate determinations for seven (A), five (B), four
(C), and four (D) independent cultures from different placentas. *,P
0.05; **, P  0.001.
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